Researchers sought to determine whether adding mogamulizumab to CHOP would improve outcomes in older patients with adult T-cell leukemia/lymphoma.

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Blood Cancer United's new research funding supports foundational science, AI, big data and global collaborations to improve patient outcomes WASHINGTON, Dec. 2, 2025 /PRNewswire/ ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate. The new CAR T-cell generation aims to mitigate exhaustion ...

VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...

Epkinly as a single agent received accelerated approval from the FDA in June 2024.

The progression of disease after first-line treatment reduces overall survival and increases all-cause mortality in patients with mantle cell lymphoma, a Swedish study reports.